In a Chinese medical market predicted to reach $2.4 trillion, famed U.S. clinics team up with private companies to get in on the action.
Investors in U.S. markets are shrugging off the risks that come with companies based in China, despite growing tensions and warnings from American regulators.
It was no garden-variety accounting scandal when Luckin Coffee inflated revenues and its stock plunged. U.S. investors have almost no recourse because of a bizarre...
The White House and Congress are moving to ban some of China’s biggest companies from the U.S. on national security grounds.
China spent big buying iconic assets in the West. That was then. Now, a slump and global pushback.
A strategic struggle over tech supremacy frames Nvidia’s pending acquisition of Mellanox.